Targeting Group II Metabotropic Glutamate (mGlu) Receptors for the Treatment of Psychosis Associated with Alzheimer's Disease: Selective Activation of mGlu2 Receptors Amplifies β-Amyloid Toxicity in Cultured Neurons, Whereas Dual Activation of mGlu2 and mGlu3 Receptors Is Neuroprotective

被引:107
作者
Caraci, Filippo [3 ]
Molinaro, Gemma [5 ]
Battaglia, Giuseppe [5 ]
Giuffrida, Maria Laura [3 ,6 ]
Riozzi, Barbara [5 ]
Traficante, Anna [5 ]
Bruno, Valeria [1 ,5 ]
Cannella, Milena [5 ]
Merlo, Sara [4 ]
Wang, Xushan [2 ]
Heinz, Beverly A. [2 ]
Nisenbaum, Eric S. [2 ]
Britton, Thomas C. [2 ]
Drago, Filippo [4 ]
Sortino, Maria Angela [4 ]
Copani, Agata [3 ,7 ]
Nicoletti, Ferdinando [1 ,5 ]
机构
[1] Univ Roma La Sapienza, Dept Physiol & Pharmacol, I-00185 Rome, Italy
[2] Eli Lilly & Co, Lilly Res Labs, Neurosci Discovery Res, Indianapolis, IN 46285 USA
[3] Univ Catania, Dept Pharmaceut Sci, Catania, Italy
[4] Univ Catania, Dept Expt & Clin Pharmacol, Catania, Italy
[5] Ist Neurol Mediterraneo Neuromed, Pozzilli, Italy
[6] Ist Nazl Biostrutture & Biosistemi, Rome, Italy
[7] CNR, Inst Biostruct & Bioimaging, Catania, Italy
关键词
ANTIPSYCHOTIC-DRUGS; SCHIZOPHRENIA; MECHANISMS; AGONIST; NEURODEGENERATION; PHARMACOLOGY; INCREASES; DEMENTIA; TRIGGERS; LY379268;
D O I
10.1124/mol.110.067488
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Dual orthosteric agonists of metabotropic glutamate 2 (mGlu2) and mGlu3 receptors are being developed as novel antipsychotic agents devoid of the adverse effects of conventional antipsychotics. Therefore, these drugs could be helpful for the treatment of psychotic symptoms associated with Alzheimer's disease (AD). In experimental animals, the antipsychotic activity of mGlu2/3 receptor agonists is largely mediated by the activation of mGlu2 receptors and is mimicked by selective positive allosteric modulators (PAMs) of mGlu2 receptors. We investigated the distinct influence of mGlu2 and mGlu3 receptors in mixed and pure neuronal cultures exposed to synthetic beta-amyloid protein (A beta) to model neurodegeneration occurring in AD. The mGlu2 receptor PAM, N-4'-cyano-biphenyl-3-yl)-N-(3-pyridinylmethyl)-ethanesulfonamide hydrochloride (LY566332), devoid of toxicity per se, amplified A beta-induced neurodegeneration, and this effect was prevented by the mGlu2/3 receptor antagonist (2S, 1'S, 2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl)glycine (LY341495). LY566332 potentiated A beta toxicity regardless of the presence of glial mGlu3 receptors, but it was inactive when neurons lacked mGlu2 receptors. The dual mGlu2/3 receptor agonist, (-)-2-oxa-4-aminobicyclo[3.1.0]exhane-4,6-dicarboxylic acid (LY379268), was neuroprotective in mixed cultures via a paracrine mechanism mediated by transforming growth factor-beta 1. LY379268 lost its protective activity in neurons grown with astrocytes lacking mGlu3 receptors, indicating that protection against A beta neurotoxicity was mediated entirely by glial mGlu3 receptors. The selective noncompetitive mGlu3 receptor antagonist, (3S)-1-(5-bromopyrimidin-2-yl)-N-(2,4-dichlorobenzyl)pyrrolidin-3-amine methanesulfonate hydrate (LY2389575), amplified A beta toxicity on its own, and, interestingly, unmasked a neurotoxic activity of LY379268, which probably was mediated by the activation of mGlu2 receptors. These data indicate that selective potentiation of mGlu2 receptors enhances neuronal vulnerability to A beta, whereas dual activation of mGlu2 and mGlu3 receptors is protective against A beta-induced toxicity.
引用
收藏
页码:618 / 626
页数:9
相关论文
共 42 条
[1]
+10 T/C polymorphisms in the gene of transforming growth factor-βI are associated with neurodegeneration and its clinical evolution [J].
Arosio, Beatrice ;
Bergamaschini, Luigi ;
Galimberti, Lorenza ;
La Porta, Caterina ;
Zanetti, Mariella ;
Calabresi, Carmen ;
Scarpini, E. ;
Annoni, Giorgio ;
Vergani, Carlo .
MECHANISMS OF AGEING AND DEVELOPMENT, 2007, 128 (10) :553-557
[2]
Probing the Biology of Alzheimer's Disease in Mice [J].
Ashe, Karen H. ;
Zahs, Kathleen R. .
NEURON, 2010, 66 (05) :631-645
[3]
Bruno V, 1998, J NEUROSCI, V18, P9594
[4]
Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings [J].
Bullock, R .
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (01) :1-10
[5]
TGF-β1 Pathway as a New Target for Neuroprotection in Alzheimer's Disease [J].
Caraci, Filippo ;
Battaglia, Giuseppe ;
Bruno, Valeria ;
Bosco, Paolo ;
Carbonaro, Viviana ;
Giuffrida, Maria Laura ;
Drago, Filippo ;
Sortino, Maria Angela ;
Nicoletti, Ferdinando ;
Copani, Agata .
CNS NEUROSCIENCE & THERAPEUTICS, 2011, 17 (04) :237-249
[6]
The mGlu2/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: possible implications for psychosis [J].
Carter, K ;
Dickerson, J ;
Schoepp, DD ;
Reilly, M ;
Herring, N ;
Williams, J ;
Sallee, FR ;
Sharp, JW ;
Sharp, FR .
NEUROPHARMACOLOGY, 2004, 47 (08) :1135-1145
[7]
Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine [J].
Cartmell, J ;
Monn, JA ;
Schoepp, DD .
PSYCHOPHARMACOLOGY, 2000, 148 (04) :423-429
[8]
mGlu3 Metabotropic Glutamate Receptors Modulate the Differentiation of SVZ-Derived Neural Stem Cells Towards the Astrocytic Lineage [J].
Ciceroni, C. ;
Mosillo, P. ;
Mastrantoni, E. ;
Sale, P. ;
Ricci-Vitiani, L. ;
Biagioni, F. ;
Stocchi, F. ;
Nicoletti, F. ;
Melchiorri, D. .
GLIA, 2010, 58 (07) :813-822
[9]
Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia [J].
Conn, P. Jeffrey ;
Lindsley, Craig W. ;
Jones, Carrie K. .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2009, 30 (01) :25-31
[10]
BETA-AMYLOID INCREASES NEURONAL SUSCEPTIBILITY TO INJURY BY GLUCOSE DEPRIVATION [J].
COPANI, A ;
KOH, JY ;
COTMAN, CW .
NEUROREPORT, 1991, 2 (12) :763-765